Blood test may speed up chemo decisions for pancreatic cancer patients
NCT ID NCT07096362
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 33 times
Summary
This study is testing whether a blood test that measures tumor DNA (ctDNA) can tell doctors within weeks if chemotherapy is working for metastatic pancreatic cancer. Currently, doctors wait about 8 weeks for a scan. The trial will enroll 50 patients and compare the blood test results with standard imaging. The goal is to see if the test can help switch treatments sooner for those who aren't responding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
5-Fluorouracil, Oxaliplatin, Leucovorin (chemotherapy drugs)
What this could lead to
If successful, this could show that a simple blood test can guide faster, more personalized chemotherapy decisions for people with metastatic pancreatic cancer.
What could go wrong
This is a small, early-phase study with only 50 participants. The blood test may not reliably predict treatment response, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.